{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T13:10:57Z","timestamp":1782479457748,"version":"3.54.5"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T00:00:00Z","timestamp":1666742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T00:00:00Z","timestamp":1666742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Acute exacerbation (AE) of systemic autoimmune disease-related interstitial lung diseases (SAID-ILD) is less common than AE of idiopathic pulmonary fibrosis (IPF) and the details of AE-SAID-ILD have not been elucidated, but the prognosis is similarly devastating. This study was undertaken to determine the incidences of AE-ILD in each SAID and to elucidate the proportion of progressive fibrosing (PF)-ILD in AE-SAID-ILD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We retrospectively analysed data for patients with SAID-ILD who were diagnosed and observed at our hospital between 1999 and 2020.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Two hundred and thirty-two patients with SAID-ILD were enrolled, with a mean observation period of 100.2\u00a0months. AE-SAID-ILD was found in 25 patients (10.78%), mainly in patients with RA (17 patients, 68%) and elderly male patients with a smoking history. The overall incidence of AE-SAID-ILD was 1.29%\/person-year, and the incidence for each SAID was as follows: RA 2.193, microscopic polyarteritis (MPA) 3.203, systemic sclerosis (SSc) 2.277, primary Sj\u00f6gren syndrome 0.426, and polymyositis\/dermatomyositis 0.222. The incidence of AE of RA\/MPA\/SSc-ILD was significantly higher than that of other AE-SAID-ILD (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Five of 25 patients (20%) fulfilled the criteria for PF-ILD. The 90-day survival rate was 48.0%, and a higher neutrophil count at AE (HR 13.27, 95%CI 2.447\u2013246, <jats:italic>p<\/jats:italic>\u2009=\u20090.001) and early commencement of long-duration direct haemoperfusion with a polymyxin B-immobilised fibre column (HR 0.105, 95%CI 0.005\u20130.858, <jats:italic>p<\/jats:italic>\u2009=\u20090.035) were significant prognostic factors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The incidence of AE-SAID-ILD was significantly higher in patients with RA, MPA, or SSc than in patients with other SAID. Furthermore, even in patients with AE-SAID-ILD, the proportion of PF-ILD just before AE was not high (20%).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12890-022-02197-3","type":"journal-article","created":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T14:03:14Z","timestamp":1666792994000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Frequency, proportion of PF-ILD, and prognostic factors in patients with acute exacerbation of ILD related to systemic autoimmune diseases"],"prefix":"10.1186","volume":"22","author":[{"given":"Noriyuki","family":"Enomoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyogo","family":"Naoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutaka","family":"Mochizuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Isayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuki","family":"Fukada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Aono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mineo","family":"Katsumata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Yasui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutaka","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Karayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironao","family":"Hozumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzo","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Furuhashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Inui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaro","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Suda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,26]]},"reference":[{"issue":"1","key":"2197_CR1","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1183\/09031936.06.00114004","volume":"27","author":"DS Kim","year":"2006","unstructured":"Kim DS, Park JH, Park BK, Lee JS, Nicholson AG, Colby T. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J. 2006;27(1):143\u201350.","journal-title":"Eur Respir J"},{"issue":"2","key":"2197_CR2","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1183\/09031936.00159709","volume":"37","author":"JW Song","year":"2011","unstructured":"Song JW, Hong SB, Lim CM, Koh Y, Kim DS. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J. 2011;37(2):356\u201363.","journal-title":"Eur Respir J"},{"issue":"7","key":"2197_CR3","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1164\/rccm.200703-463PP","volume":"176","author":"HR Collard","year":"2007","unstructured":"Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE Jr, Lasky JA, Loyd JE, Noth I, Olman MA, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2007;176(7):636\u201343.","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"2197_CR4","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","volume":"183","author":"G Raghu","year":"2011","unstructured":"Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, et al. An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788\u2013824.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"2197_CR5","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12931-016-0400-1","volume":"17","author":"T Kakugawa","year":"2016","unstructured":"Kakugawa T, Sakamoto N, Sato S, Yura H, Harada T, Nakashima S, Hara A, Oda K, Ishimoto H, Yatera K, et al. Risk factors for an acute exacerbation of idiopathic pulmonary fibrosis. Respir Res. 2016;17(1):79.","journal-title":"Respir Res"},{"issue":"4","key":"2197_CR6","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1164\/rccm.201006-0894CI","volume":"183","author":"B Ley","year":"2011","unstructured":"Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183(4):431\u201340.","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"2197_CR7","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1164\/rccm.201403-0566OC","volume":"190","author":"M Natsuizaka","year":"2014","unstructured":"Natsuizaka M, Chiba H, Kuronuma K, Otsuka M, Kudo K, Mori M, Bando M, Sugiyama Y, Takahashi H. Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences. Am J Respir Crit Care Med. 2014;190(7):773\u20139.","journal-title":"Am J Respir Crit Care Med"},{"key":"2197_CR8","doi-asserted-by":"crossref","unstructured":"Enomoto N, Homma S, Inase N, Kondoh Y, Saraya T, Takizawa H, et al. Prospective nationwide multicentre cohort study of the clinical significance of autoimmune features in idiopathic interstitial pneumonias. Thorax.\u00a02022;77:143\u2013153.","DOI":"10.1136\/thoraxjnl-2020-216263"},{"issue":"1","key":"2197_CR9","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1378\/chest.07-0323","volume":"132","author":"IN Park","year":"2007","unstructured":"Park IN, Kim DS, Shim TS, Lim CM, Lee SD, Koh Y, Kim WS, Kim WD, Jang SJ, Colby TV. Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis. Chest. 2007;132(1):214\u201320.","journal-title":"Chest"},{"key":"2197_CR10","doi-asserted-by":"publisher","first-page":"175346662093577","DOI":"10.1177\/1753466620935774","volume":"14","author":"N Enomoto","year":"2020","unstructured":"Enomoto N, Naoi H, Aono Y, Katsumata M, Horiike Y, Yasui H, Karayama M, Hozumi H, Suzuki Y, Furuhashi K, et al. Acute exacerbation of unclassifiable idiopathic interstitial pneumonia: comparison with idiopathic pulmonary fibrosis. Ther Adv Respir Dis. 2020;14:1753466620935774.","journal-title":"Ther Adv Respir Dis"},{"issue":"6","key":"2197_CR11","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.rmed.2008.12.019","volume":"103","author":"T Suda","year":"2009","unstructured":"Suda T, Kaida Y, Nakamura Y, Enomoto N, Fujisawa T, Imokawa S, Hashizume H, Naito T, Hashimoto D, Takehara Y, et al. Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases. Respir Med. 2009;103(6):846\u201353.","journal-title":"Respir Med"},{"key":"2197_CR12","doi-asserted-by":"publisher","first-page":"147997231880947","DOI":"10.1177\/1479972318809476","volume":"16","author":"N Enomoto","year":"2019","unstructured":"Enomoto N, Oyama Y, Enomoto Y, Yasui H, Karayama M, Kono M, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, et al. Differences in clinical features of acute exacerbation between connective tissue disease-associated interstitial pneumonia and idiopathic pulmonary fibrosis. Chron Respir Dis. 2019;16:1479972318809476.","journal-title":"Chron Respir Dis"},{"issue":"5","key":"2197_CR13","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/resp.13682","volume":"25","author":"A Suzuki","year":"2020","unstructured":"Suzuki A, Kondoh Y, Brown KK, Johkoh T, Kataoka K, Fukuoka J, Kimura T, Matsuda T, Yokoyama T, Fukihara J, et al. Acute exacerbations of fibrotic interstitial lung diseases. Respirology. 2020;25(5):525\u201334.","journal-title":"Respirology"},{"issue":"5","key":"2197_CR14","doi-asserted-by":"publisher","first-page":"103056","DOI":"10.1016\/j.autrev.2022.103056","volume":"21","author":"M Akiyama","year":"2022","unstructured":"Akiyama M, Kaneko Y. Pathogenesis, clinical features, and treatment strategy for rheumatoid arthritis-associated interstitial lung disease. Autoimmun Rev. 2022;21(5):103056.","journal-title":"Autoimmun Rev"},{"issue":"11","key":"2197_CR15","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.3390\/diagnostics11111960","volume":"11","author":"B Ruaro","year":"2021","unstructured":"Ruaro B, Baratella E, Confalonieri P, Wade B, Marrocchio C, Geri P, Busca A, Pozzan R, Andrisano AG, Cova MA, et al. High-Resolution Computed Tomography: Lights and Shadows in Improving Care for SSc-ILD Patients. Diagnostics (Basel). 2021;11(11):1960.","journal-title":"Diagnostics (Basel)"},{"issue":"9","key":"2197_CR16","doi-asserted-by":"publisher","first-page":"e003132","DOI":"10.1136\/bmjopen-2013-003132","volume":"3","author":"H Hozumi","year":"2013","unstructured":"Hozumi H, Nakamura Y, Johkoh T, Sumikawa H, Colby TV, Kono M, Hashimoto D, Enomoto N, Fujisawa T, Inui N, et al. Acute exacerbation in rheumatoid arthritis-associated interstitial lung disease: a retrospective case control study. BMJ Open. 2013;3(9):e003132.","journal-title":"BMJ Open"},{"issue":"1","key":"2197_CR17","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/s12931-021-01856-z","volume":"22","author":"M Qiu","year":"2021","unstructured":"Qiu M, Jiang J, Nian X, Wang Y, Yu P, Song J, Zou S. Factors associated with mortality in rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis. Respir Res. 2021;22(1):264.","journal-title":"Respir Res"},{"issue":"4","key":"2197_CR18","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1093\/rheumatology\/keab615","volume":"61","author":"M Orlandi","year":"2022","unstructured":"Orlandi M, Landini N, Sambataro G, Nardi C, Tofani L, Bruni C, Bellando-Randone S, Blagojevic J, Melchiorre D, Hughes M, et al. The role of chest CT in deciphering interstitial lung involvement: systemic sclerosis versus COVID-19. Rheumatology (Oxford). 2022;61(4):1600\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"2197_CR19","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/art.41105","volume":"72","author":"H Tsuji","year":"2020","unstructured":"Tsuji H, Nakashima R, Hosono Y, Imura Y, Yagita M, Yoshifuji H, Hirata S, Nojima T, Sugiyama E, Hatta K, et al. Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis. Arthritis Rheumatol. 2020;72(3):488\u201398.","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"2197_CR20","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1093\/rheumatology\/kep052","volume":"48","author":"T Sawada","year":"2009","unstructured":"Sawada T, Inokuma S, Sato T, Otsuka T, Saeki Y, Takeuchi T, Matsuda T, Takemura T, Sagawa A. Study Committee for Leflunomide-induced Lung Injury JCoR: Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis. Rheumatology (Oxford). 2009;48(9):1069\u201372.","journal-title":"Rheumatology (Oxford)"},{"issue":"18","key":"2197_CR21","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","volume":"381","author":"KR Flaherty","year":"2019","unstructured":"Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, Richeldi L, Kolb M, Tetzlaff K, Stowasser S, et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med. 2019;381(18):1718\u201327.","journal-title":"N Engl J Med"},{"issue":"3","key":"2197_CR22","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1164\/rccm.201604-0801CI","volume":"194","author":"HR Collard","year":"2016","unstructured":"Collard HR, Ryerson CJ, Corte TJ, Jenkins G, Kondoh Y, Lederer DJ, Lee JS, Maher TM, Wells AU, Antoniou KM, et al. Acute exacerbation of idiopathic pulmonary fibrosis. an international working group report. Am J Respir Crit Care Med. 2016;194(3):265\u201375.","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"2197_CR23","doi-asserted-by":"publisher","first-page":"684","DOI":"10.7326\/0003-4819-156-10-201205150-00004","volume":"156","author":"B Ley","year":"2012","unstructured":"Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, Poletti V, Buccioli M, Elicker BM, Jones KD, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012;156(10):684\u201391.","journal-title":"Ann Intern Med"},{"issue":"1","key":"2197_CR24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.resinv.2014.08.003","volume":"53","author":"S Homma","year":"2015","unstructured":"Homma S, Sugino K, Sakamoto S. Usefulness of a disease severity staging classification system for IPF in Japan: 20 years of experience from empirical evidence to randomized control trial enrollment. Respir Investig. 2015;53(1):7\u201312.","journal-title":"Respir Investig"},{"issue":"10","key":"2197_CR25","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/j.rmed.2013.08.008","volume":"107","author":"N Enomoto","year":"2013","unstructured":"Enomoto N, Suda T, Kono M, Kaida Y, Hashimoto D, Fujisawa T, Inui N, Nakamura Y, Imokawa S, Funai K, et al. Amount of elastic fibers predicts prognosis of idiopathic pulmonary fibrosis. Respir Med. 2013;107(10):1608\u201316.","journal-title":"Respir Med"},{"issue":"4","key":"2197_CR26","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1164\/rccm.200709-1365OC","volume":"178","author":"M Akira","year":"2008","unstructured":"Akira M, Kozuka T, Yamamoto S, Sakatani M. Computed tomography findings in acute exacerbation of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2008;178(4):372\u20138.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"2197_CR27","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 2013;48(3):452\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"2197_CR28","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12890-015-0004-4","volume":"15","author":"N Enomoto","year":"2015","unstructured":"Enomoto N, Mikamo M, Oyama Y, Kono M, Hashimoto D, Fujisawa T, Inui N, Nakamura Y, Yasuda H, Kato A, et al. Treatment of acute exacerbation of idiopathic pulmonary fibrosis with direct hemoperfusion using a polymyxin B-immobilized fiber column improves survival. BMC Pulm Med. 2015;15:15.","journal-title":"BMC Pulm Med"},{"issue":"3","key":"2197_CR29","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/j.1440-1843.2008.01290.x","volume":"13","author":"N Enomoto","year":"2008","unstructured":"Enomoto N, Suda T, Uto T, Kato M, Kaida Y, Ozawa Y, Miyazaki H, Kuroishi S, Hashimoto D, Naito T, et al. Possible therapeutic effect of direct haemoperfusion with a polymyxin B immobilized fibre column (PMX-DHP) on pulmonary oxygenation in acute exacerbations of interstitial pneumonia. Respirology. 2008;13(3):452\u201360.","journal-title":"Respirology"},{"issue":"9","key":"2197_CR30","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","volume":"205","author":"G Raghu","year":"2022","unstructured":"Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, Kreuter M, Lynch DA, Maher TM, Martinez FJ, et al. Idiopathic pulmonary fibrosis (an Update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2022;205(9):e18\u201347.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"2197_CR31","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12931-019-1022-1","volume":"20","author":"M Kolb","year":"2019","unstructured":"Kolb M, Vasakova M. The natural history of progressive fibrosing interstitial lung diseases. Respir Res. 2019;20(1):57.","journal-title":"Respir Res"},{"issue":"11","key":"2197_CR32","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1080\/03007995.2019.1647040","volume":"35","author":"M Wijsenbeek","year":"2019","unstructured":"Wijsenbeek M, Kreuter M, Olson A, Fischer A, Bendstrup E, Wells CD, Denton CP, Mounir B, Zouad-Lejour L, Quaresma M, et al. Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management. Curr Med Res Opin. 2019;35(11):2015\u201324.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"2197_CR33","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s12931-021-01879-6","volume":"22","author":"BS Kwon","year":"2021","unstructured":"Kwon BS, Choe J, Chae EJ, Hwang HS, Kim YG, Song JW. Progressive fibrosing interstitial lung disease: prevalence and clinical outcome. Respir Res. 2021;22(1):282.","journal-title":"Respir Res"},{"key":"2197_CR34","unstructured":"Naccache JM, Jouneau S, Didier M, Borie R, Cachanado M, Bourdin A, et al. Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med.\u00a02022;10(1):26\u201334."},{"issue":"8","key":"2197_CR35","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1111\/resp.13506","volume":"24","author":"H Hozumi","year":"2019","unstructured":"Hozumi H, Hasegawa H, Miyashita K, Yasui H, Suzuki Y, Kono M, Karayama M, Furuhashi K, Hashimoto D, Enomoto N, et al. Efficacy of corticosteroid and intravenous cyclophosphamide in acute exacerbation of idiopathic pulmonary fibrosis: A propensity score-matched analysis. Respirology. 2019;24(8):792\u20138.","journal-title":"Respirology"},{"issue":"6","key":"2197_CR36","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.resinv.2021.05.008","volume":"59","author":"K Tanaka","year":"2021","unstructured":"Tanaka K, Enomoto N, Hozumi H, Isayama T, Naoi H, Aono Y, Katsumata M, Yasui H, Karayama M, Suzuki Y, et al. Serum S100A8 and S100A9 as prognostic biomarkers in acute exacerbation of idiopathic pulmonary fibrosis. Respir Investig. 2021;59(6):827\u201336.","journal-title":"Respir Investig"},{"issue":"4","key":"2197_CR37","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1159\/000287232","volume":"29","author":"S Abe","year":"2010","unstructured":"Abe S, Seo Y, Hayashi H, Matsuda K, Usuki J, Azuma A, Kudoh S, Gemma A. Neutrophil adsorption by polymyxin B-immobilized fiber column for acute exacerbation in patients with interstitial pneumonia: a pilot study. Blood Purif. 2010;29(4):321\u20136.","journal-title":"Blood Purif"},{"issue":"12","key":"2197_CR38","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.2169\/internalmedicine.51.6965","volume":"51","author":"S Abe","year":"2012","unstructured":"Abe S, Azuma A, Mukae H, Ogura T, Taniguchi H, Bando M, Sugiyama Y. Polymyxin B-immobilized fiber column (PMX) treatment for idiopathic pulmonary fibrosis with acute exacerbation: a multicenter retrospective analysis. Intern Med. 2012;51(12):1487\u201391.","journal-title":"Intern Med"},{"issue":"22","key":"2197_CR39","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071\u201382.","journal-title":"N Engl J Med"},{"issue":"1","key":"2197_CR40","doi-asserted-by":"publisher","first-page":"15620","DOI":"10.1038\/s41598-020-72607-1","volume":"10","author":"J Kang","year":"2020","unstructured":"Kang J, Han M, Song JW. Antifibrotic treatment improves clinical outcomes in patients with idiopathic pulmonary fibrosis: a propensity score matching analysis. Sci Rep. 2020;10(1):15620.","journal-title":"Sci Rep"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-022-02197-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-022-02197-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-022-02197-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T14:03:25Z","timestamp":1666793005000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-022-02197-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,26]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2197"],"URL":"https:\/\/doi.org\/10.1186\/s12890-022-02197-3","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,26]]},"assertion":[{"value":"26 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the ethics committee of Hamamatsu University School of Medicine (approval number 18\u2013085). All procedures in this study were performed in accordance with the study protocol and the 1964 Helsinki declaration as amended.The need for informed consent was waived by the ethics committee of Hamamatsu University School of Medicine, because of the retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declared no potential conflicts of interest with respect to the research, authorship, and\/or publication of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"387"}}